| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Biovac nets $108M finance package to build Africa's first fully integrated vaccine plant | ||
| Mo | Biogen bullish on America with Durham Bulls team up | ||
| Mo | Bayer falls short in bid to block J&J's survival claims in prostate cancer clash | ||
| Mo | AbbVie launches 'PSO Done' psoriasis campaign with cross-agency effort | ||
| Mo | Theramex exits self-regulatory body after 'systemic' compliance failures | ||
| 17.04. | FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER | ||
| 17.04. | Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat | ||
| 17.04. | Fierce Pharma Asia-Astellas' stem cell therapy rethink; GSK's bullish ADC plan; Daiichi's OTC sale | ||
| 17.04. | BIO comes out swinging with 'Fight of Our Lives' campaign for the industry's 50th birthday | ||
| 16.04. | Viatris, Teva kick off separate recalls over dissolution, raw material issues | ||
| 16.04. | 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again | ||
| 16.04. | Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy | ||
| 16.04. | Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel | ||
| 16.04. | Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover | ||
| 15.04. | In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory | ||
| 15.04. | Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough' | ||
| 15.04. | Novartis CEO Vas Narasimhan joins Anthropic's board as biopharma's ties to AI deepen | ||
| 15.04. | Astellas manufacturing chief views reliable supply, bridging research as his production 'north star' | ||
| 15.04. | Teva launches new online schizophrenia community project | ||
| 15.04. | Pfizer recruits former Angel Lucy Liu for latest mission against cancer | ||
| 15.04. | Ionis exec shares method to the Madness after 2026 Drug Name Tournament win | ||
| 14.04. | FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo | ||
| 14.04. | J&J, chasing $100B year, sports immunology 'dual powerhouse' of Tremfya and new launch Icotyde | ||
| 14.04. | Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions | ||
| 14.04. | Pfizer rebuked by FDA for misleading Adcetris ads on Facebook |